EVEREST MED (01952) major shareholders increase holdings again, commercialization turning point and pipeline realization support long-term confidence

Today, EVEREST MED (01952) announced that the company's non-executive director, honorary chairman of the board, and main shareholder Fu Wei, purchased 660,000 ordinary shares of the company through the open market on May 14, involving approximately HK$20.7 million, at an average price of about HK$31.25 per share. Fu Wei stated that this increase in holdings was based on a firm confidence in EVEREST MED's future prospects and long-term development. He did not rule out the possibility of further increasing the company's shares in the future, under the premise of compliance with relevant laws and regulations. From a market perspective, this is not a one-off action, but a continuation of the company's main shareholders and core management's optimistic view of the company. As early as December 12, 2025, Fu Wei, together with executive directors and chairman of the board Wu Yifang, CEO Luo Yongqing, and CFO He Ying, among other core management members, collectively increased their holdings by 846,700 shares of the company through the open market, investing over HK$38 million. At the same time, as a major shareholder, Kangqiao Capital also stated its plan to further increase its holdings in the company in the next three to six months, forming a double endorsement from management and capital, and sending a clear long-term positive signal to the market. The continuous increase in holdings reflects the underlying fundamental logic of the deep-seated changes taking place within EVEREST MED. In 2025, the company's operating performance reached a critical turning point. Annual report data showed a 142% year-on-year increase in revenue to HK$1.707 billion, with a significant improvement in commercialization capabilities. Of more market interest is the company's loss under international financial standards narrowing significantly by 71%, and for the first time under non-international financial standards, turning a loss into a profit of RMB 187 million, operating cash flow turning positive, cash reserves remaining adequate, and overall operating quality steadily improving. For an innovative pharmaceutical company, this means that EVEREST MED has proven its ability to achieve scalable income and sustainable loss reduction, and has begun to establish a self-generating capacity and a positive commercialization cycle. In 2025, after excluding non-cash items, the company's gross profit margin was 74.1%, reflecting continued optimization of the product portfolio structure and enhanced economies of scale. In 2026, as the year for the company's "2030 Strategy" advancement, it is expected that the core product Nafucan will achieve sales revenue of between HK$2.4 billion and HK$2.6 billion, becoming the main engine of performance growth. At the same time, Weishiping and Yijia are expected to start medical insurance negotiations within the year, and if successfully included in the medical insurance system, patient coverage and market penetration rates are expected to further increase. Meanwhile, the company's innovative pipeline is also entering a phase of intensive realization. The approval of Ezetimibe nasal spray (proposed trade name: Xingbituo) in mainland China is expected in the third quarter of 2026; and the third-generation PCSK9 inhibitor lipid-lowering drug Leribole is expected to submit a China biological product license application (BLA) in the first half of 2026. In the industry's view, EVEREST MED is currently entering a phase of "dual-wheel drive," where commercialization expansion and the realization of innovative research and development achievements are proceeding in parallel. On the one hand, core commercial products continue to contribute stable cash flow and performance growth; on the other hand, self-developed and global pipeline projects are constantly advancing, driving the company's long-term value to continue to open up. Against this backdrop, Fu Wei, as a major shareholder of the company and founder and CEO of Kangqiao Capital, along with Kangqiao Capital's previous commitments to increase holdings, forms a double endorsement from core shareholders and capital, undoubtedly sending a clear signal to the market: with the formation of a closed commercial loop and the intensive landing of the pipeline, the revaluation of EVEREST MED's value may just be beginning.